4-Aminomethyltetrahydropyran → HCID 71715228, compound

HRID 575163Notes

Reaction equation

HRID 575163 reaction equation
[C:1]([C:4]1[N:5]=[C:6]2[C:12]3[CH:13]=[C:14]([C:18]#[C:19][C:20]([OH:23])([CH3:22])[CH3:21])[C:15]([F:17])=[CH:16][C:11]=3[O:10][CH2:9][CH2:8][N:7]2[C:24]=1[C:25]([OH:27])=O)(=[O:3])[NH2:2].[O:28]1[CH2:33][CH2:32][CH:31]([CH2:34][NH2:35])[CH2:30][CH2:29]1>>[F:17][C:15]1[C:14]([C:18]#[C:19][C:20]([OH:23])([CH3:21])[CH3:22])=[CH:13][C:12]2[C:6]3[N:7]([C:24]([C:25]([NH:35][CH2:34][CH:31]4[CH2:32][CH2:33][O:28][CH2:29][CH2:30]4)=[O:27])=[C:4]([C:1]([NH2:2])=[O:3])[N:5]=3)[CH2:8][CH2:9][O:10][C:11]=2[CH:16]=1

Participants

3

Procedure

2-Carbamoyl-9-fluoro-10-(3-hydroxy-3-methyl-but-1-ynyl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-3-carboxylic acid (0.05 g) was reacted with 1-tetrahydro-2H-pyran-4-ylmethanamine similar to as described in Example 2 to afford 6 mg of 9-fluoro-10-(3-hydroxy-3-methyl-but-1-ynyl)-N3-(tetrahydropyran-4-ylmethyl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2,3-dicarboxamide following reverse phase hplc purification. MS (Q1) 471 (M)+. NMR (400 MHz, DMSO) δ 11.30 (t, J=5.4 Hz, 1H), 8.60 (d, J=8.4 Hz, 1H), 8.38 (s, 1H), 7.89 (s, 1H), 7.01 (d, J=10.6 Hz, 1H), 5.47 (s, 1H), 5.05-4.97 (m, 2H), 4.59-4.51 (m, 2H), 3.91-3.74 (m, 3H), 3.19 (t, J=6.0 Hz, 2H), 1.82-1.67 (m, 1H), 1.67-1.58 (m, 2H), 1.49 (s, 6H), 1.32-1.18 (m, 3H).

Sources & evidence

ORD record
ord-b4c3c5dc194b437db95fc733f7390285
Source dataset
uspto-grants-2015_05
Patent number
US09034866B2

Reaction notes

Loading…